The novel nicotinic receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [3H]norepinephrine overflow from rat hippocampal slices

Biochemical Pharmacology

Volumn 78, Issue 7, 2009, Pages 889-897

  Smith, Andrew M ^a   Dhawan, Gurpreet K ^a   Zhang, Zhenfa ^a   Siripurapu, Kiran B ^a   Crooks, Peter A ^a   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

Author keywords

Antidepressants; Nicotine; Nicotinic acetylcholine receptor; Norepinephrine release; Smoking cessation

Indexed keywords

DOPAMINE; MECAMYLAMINE; METHYLLYCACONITINE; N,N' DODECANE 1,12 DIYL BIS 3 PICOLINIUM BROMIDE; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; TRITIUM; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; BRAIN PERFUSION; BRAIN SLICE; CIGARETTE SMOKING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DISEASE ASSOCIATION; DOPAMINE RELEASE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

ACONITINE; ALLOSTERIC REGULATION; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MALE; MECAMYLAMINE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; NOREPINEPHRINE; PICOLINES; RATS; RATS, SPRAGUE-DAWLEY; TRITIUM;

EID: 68349155682     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.010     Document Type: Article

References (58)

1. Le Foll B., and Goldberg S.R. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 192 (2009) 335-367
2. Rose J.E. Disrupting nicotine reinforcement: from cigarette to brain. Ann NY Acad Sci 1141 (2008) 233-256
3. Benowitz N.L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Ann Rev Pharmacol Toxicol 49 (2009) 57-71
4. Glassman A.H., Helzer J.E., Covey L.S., Cottler L.B., Stetner F., Tipp J.E., et al. Smoking, smoking cessation, and major depression. JAMA 264 (1990) 1546-1549
5. Berlin I., and Covey L.S. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction 101 (2006) 1814-1821
6. Covey L.S., Glassman A.H., Jiang H., Fried J., Masmela J., LoDuca C., et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction 102 (2007) 1292-1302
7. Covey L.S. Tobacco cessation among patients with depression. Prim Care 26 (1999) 691-706
8. Covey L.S., Glassman A.H., and Stetner F. Major depression following smoking cessation. Am J Psychiatry 154 (1997) 263-265
9. Ferry L.H., and Burchette R.J. Bupropion for smoking cessation in non-depressed smokers. J Addict Dis 13 (1994) 249
10. Benowitz N.L., and Peng M.W. Non-nicotine pharmacotherapy for smoking cessation. CNS Drugs 13 (2000) 265-285
11. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, Issue 1.
12. 3H]norepinephrine. J Pharmacol Exp Ther 302 (2002) 1113-1122
13. Sidhpura N., Redfern P., and Wonnacott S. Comparison of the effects of bupropion on nicotinic receptor-evoked [(3)H]dopamine release from rat striatal synaptosomes and slices. Eur J Pharmacol 567 (2007) 102-109
14. da Costa C.L., Younes R.N., and Lourenco M.T. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122 (2002) 403-408
15. Hughes J.R., Stead L.F., and Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 7 (2005) 491-499
16. Montgomery S.A. Is there a role for a pure noradrenergic drug in the treatment of depression?. Eur Neuropsychopharmacol 7 Suppl. 1 (1997) S3-S9 discussion S71-3
17. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47 (2000) 818-829
18. Miller D.K., Wong E.H., Chesnut M.D., and Dwoskin L.P. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302 (2002) 687-695
19. Rauhut A.S., Mullins S.N., Dwoskin L.P., and Bardo M.T. Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303 (2002) 664-672
20. Lundahl L.H., Henningfield J.E., and Lukas S.E. Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav 66 (2000) 637-643
21. Rose J.E. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology 184 (2006) 274-285
22. Rose J.E., Behm F.M., Westman E.C., Levin E.D., Stein R.M., and Ripka G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56 (1994) 86-99
23. Dwoskin L.P., Wooters T.E., Sumithran S.P., Siripurapu K.B., Joyce B.M., Lockman P.R., et al. N,N′-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-induced dopamine release and hyperactivity. J Pharmacol Exp Ther 326 (2008) 563-576
24. Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., and Bardo M.T. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology 52 (2007) 755-763
25. Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., and Bardo M.T. Effect of a novel nicotinic receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology 184 (2006) 426-434
26. Dwoskin L.P., Sumithran S.P., Zhu J., Deaciuc A.G., Ayers J.T., and Crooks P.A. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett 14 (2004) 1863-1867
27. Grinevich V.P., Crooks P.A., Sumithran S.P., Haubner A.J., Ayers J.T., and Dwoskin L.P. N-n-alkylpyridinium analogs, a novel class of nicotinic receptor antagonists: selective inhibition of nicotine-evoked [3H] dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther 306 (2003) 1011-1020
28. 3H]dopamine overflow from superfused rat striatal slices. J Pharmacol Exp Ther 301 (2002) 1088-1096
29. Dani J.A., and Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Ann Rev Pharmacol Toxicol 47 (2007) 699-729
30. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65 (2004) 1526-1535
31. Amtage F., Neughebauer B., McIntosh J.M., Freiman T., Zentner J., Feuerstein T.J., et al. Characterization of nicotinic receptors inducing noradrenaline release and absence of nicotinic autoreceptors in human neocortex. Brain Res Bull 62 (2004) 413-423
32. 3H]-dopamine release. Br J Pharmacol 117 (1996) 595-606
33. 3H]norepinephrine from developing and adult rat hippocampus: direct and indirect mechanisms. Neuropharmacology 42 (2002) 653-661
34. Sacaan A.I., Dunlop J.L., and Lloyd G.K. Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J Pharmacol Exp Ther 274 (1995) 224-230
35. Sershen H., Balla A., Lajtha A., and Vizi E.S. Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus. Neuroscience 77 (1997) 121-130
36. Balfour D.J., and Fagerstrom K.O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72 (1996) 51-81
37. Summers K.L., and Giacobini E. Effects of local and repeated systemic administration of (-)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 20 (1995) 753-759
38. Linner L., Endersz H., Ohman D., Bengtsson F., Schalling M., and Svensson T.H. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 297 (2001) 540-546
39. Benowitz N.L., and Jacob III P. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35 (1984) 499-504
40. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190 (2007) 269-319
41. Ghosheh O.A., Dwoskin L.P., Miller D.K., and Crooks P.A. Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2′-(14)C]nicotine. Drug Metab Disposit 29 (2001) 645-651
42. Dineley-Miller K., and Patrick J. Gene transcripts for the nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system. Brain Res Mol Brain Res 16 (1992) 339-344
43. Le Novere N., Zoli M., and Changeux J.P. Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci 8 (1996) 2428-2439
44. Lena C., de Kerchove D'Exaerde A., Cordero-Erausquin M., Le Novere N., del Mar Arroyo-Jimenez M., and Changeux J.P. Diversity and distribution of nicotinic acetylcholine receptors in the locus ceruleus neurons. Proc Natl Acad Sci USA 96 (1999) 12126-12131
45. Vincler M.A., and Eisenach J.C. Immunocytochemical localization of the alpha3, alpha4, alpha5, alpha7, beta2, beta3 and beta4 nicotinic acetylcholine receptor subunits in the locus coeruleus of the rat. Brain Res 974 (2003) 25-36
46. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., et al. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol 284 (1989) 314-335
47. 3H]norepinephrine release from mouse hippocampal synaptosomes. Mol Pharmacol 70 (2006) 967-976
48. Luo S., Kulak J.M., Cartier G.E., Jacobsen R.B., Yoshikami D., Olivera B.M., et al. Alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci 18 (1998) 8571-8579
49. Kulak J.M., Nguyen T.A., Olivera B.M., and McIntosh J.M. Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J Neurosci 17 (1997) 5263-5270
50. Le Novere N., and Changeux J.P. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 40 (1995) 155-172
51. Westphalen R.I., Gomez R.S., and Hemmings Jr. H.C. Nicotinic receptor-evoked hippocampal norepinephrine release is highly sensitive to inhibition by isoflurane. Br J Anaesth 102 (2009) 355-360
52. Fu Y., Matta S.G., James T.J., and Sharp B.M. Nicotine-induced norepinephrine release in the rat amygdala and hippocampus is mediated through brainstem nicotinic cholinergic receptors. J Pharmacol Exp Ther 284 (1998) 1188-1196
53. Barik J., and Wonnacott S. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol 69 (2006) 618-628
54. Ji D., and Dani J.A. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83 (2000) 2682-2690
55. Rahman S., Zhang Z., Papke R.L., Crooks P.A., Dwoskin L.P., and Bardo M.T. Region-specific effects of N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo. Br J Pharmacol 153 (2008) 792-804
56. 3H]dopamine release. Neuropharmacology 48 (2005) 72-79
57. Mogg A.J., Whiteaker P., McIntosh J.M., Marks M., Collins A.C., and Wonnacott S. Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther 302 (2002) 197-204
58. Albayati Z.A., Dwoskin L.P., and Crooks P.A. Pharmacokinetics of the novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab Dispos 36 (2008) 2024-2029